Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Sean Janzen who wrote (1432)	3/16/2000 5:07:00 PM
From: Luc Richard	Respond to of 1501

Sean, I agree with you. I bought the stock in November 1996 and I said to a lot of people to buy it... and stay with it. It was not easy after when you saw the stock below .50 but I know now that we are possibly right. So, what's the future? If their business plan is OK, your target seems to me a little bit low... I'm sure you think bigger than that... Regards, Luc

To: Sean Janzen who wrote (1432)	3/16/2000 10:48:00 PM
From: Bob Schommer	Respond to of 1501

Sean & Luc: I am long from late 1996 and understand what it is to drag anchor with IZP but all along I have imputed a lot of clinical value to apanol and the growing pipeline so I've held course; our patience will likely be well rewarded. The sails are hoisted on this ship and we are out of the harbor now. I hold similar price targets and time lines but can see this stock trading much higher than $40 if the suggestive efficacy data and side effect profiles hold and we get washed out of phase III intact. I still can't believe this stock is as cheap as it is with their pipeline and prospects. Regards, Bob